JAK2 (Janus kinase 2)

PTPN1 may inhibit T cell proliferation via the JAK2-STAT5 axis while simultaneously advancing liver cancer progression by activating the PI3K-AKT pathway in cancer cells. These findings suggest that PTPN1 could serve as a promising target for immunotherapy in liver cancer.

Readily assessable clinical and laboratory parameters can refine risk prediction for thrombosis and survival outcomes in ET. Further research is warranted to validate findings and inform individualized management approaches.

Demographic characteristics were comparable across groups, though comorbidities were more frequent in MPNs. Laboratory analyses confirmed expected disease-specific differences, including elevated leukocyte, neutrophil, and platelet counts in MPNs and prolonged activated partial thromboplastin time in hemophilia A. Circulating citrullinated histone H3 (cit-H3) levels differed significantly among groups (p < 0.001), being lowest in controls, intermediate in MPNs, and highest in hemophilia A. Within disease groups, cit-H3 levels were unaffected by clinical variables such as MPN subtype, aspirin use, phlebotomy history, or factor replacement regimen.ConclusionsElevated circulating cit-H3 levels, suggestive of increased NETosis activity, were observed in both thrombosis-prone MPNs and bleeding-prone hemophilia A. These exploratory findings suggest a possible association between NET formation and thromboinflammatory processes across distinct hemostatic disorders.

Although gemcitabine-based regimens remain widely utilized, the molecular pathways that influence treatment-associated biological variation are incompletely understood...Conversely, genomic alterations within the JAK/STAT pathway are uncommon, indicating that pathway activity may be regulated predominantly through non-genomic mechanisms. These findings demonstrate the utility of conversational artificial intelligence agents for rapid, scalable, and clinically contextualized pathway interrogation and support future studies integrating multi-omic data to refine precision medicine strategies in PDAC.

Maternal and neonatal outcomes were favorable. With careful multidisciplinary management, pregnancy in women with stable BCS is feasible.

Moreover, N-acetylcysteine inhibited CCCP-induced reactive oxygen species production, prevented mitochondrial translocation of p210 BCR-ABL, and fully restored ERK-activation. These findings suggest that intercellular relocation of p210 BCR-ABL dynamically rewires downstream signaling networks, potentially optimizing the signaling balance required for CML cell survival and proliferation.

Patients with specific chimeric RNAs, such as BRAF and JAK2, exhibited favorable responses to trametinib or ruxolitinib, and those with more neoantigens may benefit from immunotherapy. In subcutaneous xenograft models, tumors bearing Ctsc-Rab38 responded better to anti-PD1 therapy, highlighting its potential as a biomarker and therapeutic target. These findings indicate that chimeric RNAs can produce novel fusion proteins and neoantigens, disrupt the expression and function of partner genes, and guide clinical treatment stratification in ESCC.

Our literature review identified three previously reported cases of HU-associated digital gangrene, though limited to the lower extremities - two in chronic myeloid leukemia (CML) and one in sickle cell disease (SCD). In each case, gangrene developed after prolonged HU exposure, alternative etiologies were not substantiated, and stabilization or clinical improvement followed HU withdrawal. The present case aligns with this pattern while extending the reported phenotype to well-controlled PV and upper-extremity digits. Given the small number of reported cases, the pathophysiology remains incompletely defined and is largely extrapolated from studies of more frequently described HU-associated ulceration, histopathologic reports of HU-related tissue injury, and in vitro studies of HU effects on endothelial and circulating cells. Plausible mechanisms include cumulative endothelial injury, localized thrombo-occlusive microvascular dysfunction, impaired vascular and cutaneous repair, and interaction with PV-related microvascular susceptibility. Clinicians should include HU-associated vasculopathy in the differential diagnosis of otherwise unexplained digital ischemia, as prompt drug cessation may limit progression and improve digit salvage.

P=N/A, N=14, Enrolling by invitation, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting --> Enrolling by invitation

Persistent unexplained thrombocytosis with prior arterial thrombosis should raise suspicion for an occult myeloproliferative neoplasm, whereas postoperative HIT remains a clinical consideration despite negative functional assays, particularly in the context of potent P2Y12 receptor inhibition.

In the latter, the observed CV risk might stem from failure of JAKi to fully inhibit prothrombotic pathways induced by cytokines (TNF and IL-17) and the potential dose-related vascular toxicity. Understanding these binary effects will provide new insights into the divergent CV impact of JAKi.